INT33733

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1986
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 3.86
Pain Relevance 0.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (ITGA2B) plasma membrane (ITGA2B)
Anatomy Link Frequency
platelet 4
macrophages 1
monocytes 1
neutrophil 1
ITGA2B (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 7 96.64 Very High Very High Very High
agonist 12 96.40 Very High Very High Very High
ischemia 47 80.16 Quite High
local anesthetic 2 75.00 Quite High
adenocard 5 67.84 Quite High
anesthesia 5 50.00 Quite Low
antagonist 4 50.00 Quite Low
aspirin 4 25.00 Low Low
Inflammation 8 11.08 Low Low
Pain 1 10.00 Low Low
Disease Link Frequency Relevance Heat
Adhesions 65 100.00 Very High Very High Very High
Thrombosis 21 99.00 Very High Very High Very High
Heart Rate Under Development 9 98.40 Very High Very High Very High
Cv General 3 Under Development 7 96.64 Very High Very High Very High
Disease 14 96.16 Very High Very High Very High
Myocardial Infarction 26 93.68 High High
Injury 56 92.52 High High
Death 6 84.08 Quite High
Cv Unclassified Under Development 48 80.16 Quite High
Acute Coronary Syndrome 4 77.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
-act cga gcg ttg ctg cag gga gta-3?
gta Binding (act) of
1) Confidence 0.36 Published 2010 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2898415 Disease Relevance 0 Pain Relevance 0
New antiplatelet agents that block the binding sites on GPIIb/IIIa are efficacious in arterial thrombosis animal models and are now being evaluated in human disease.
GPIIb Binding (binding) of associated with disease and thrombosis
2) Confidence 0.36 Published 1995 Journal Eur. Heart J. Section Abstract Doc Link 8869013 Disease Relevance 0.36 Pain Relevance 0
Thus, inhibition of GPIIb/IIIa receptor promotes platelet-neutrophil adhesion, but markedly reduces the binding density of platelets in the coaggregates.
GPIIb Binding (binding) of in neutrophil associated with adhesions
3) Confidence 0.36 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10064007 Disease Relevance 0.29 Pain Relevance 0.16
100, to detect the activated GPIIb/IIIa receptor, Becton Dickinson, San Jose, CA), mouse anti-human CD42b:RPE-Cy5 and mouse anti-human CD38:RPE (1?
GPIIb Binding (receptor) of
4) Confidence 0.36 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2735777 Disease Relevance 0.16 Pain Relevance 0
Interestingly, gpIIb/IIIa Mabs cross-reacts with the leukocyte integrin Mac-1 receptor on activated monocytes and macrophages and blocks adhesion to fibrinogen and ICAM-1 [25], which has also been implicated in the leukocyte recruitment associated with I/R [26].
gpIIb Binding (cross) of in macrophages associated with adhesions
5) Confidence 0.36 Published 2002 Journal BMC Cardiovasc Disord Section Body Doc Link PMC117121 Disease Relevance 0.87 Pain Relevance 0
Multivariate analysis confirmed the independent association of only HPA-3a/3b and HPA-3b/3b genotypes with VOC.
HPA-3a Binding (association) of
6) Confidence 0.35 Published 2009 Journal Eur. J. Haematol. Section Body Doc Link 19702628 Disease Relevance 0.08 Pain Relevance 0
Glycoprotein (GP) IIb/IIIa inhibitors block the final common pathway of platelet aggregation by preventing fibrinogen from binding to the GP IIb/IIIa platelet receptor.
GP IIb Binding (binding) of in platelet
7) Confidence 0.35 Published 2000 Journal J. Thromb. Thrombolysis Section Abstract Doc Link 10947917 Disease Relevance 0.91 Pain Relevance 0.38
Inhibitors of the platelet glycoprotein gpIIb/IIIa have been designed, which interfere with the ability of these receptors to bind fibrinogen and thus to form platelet aggregates.
gpIIb Binding (bind) of in platelet
8) Confidence 0.35 Published 2002 Journal BMC Cardiovasc Disord Section Body Doc Link PMC117121 Disease Relevance 0.32 Pain Relevance 0
In contrast, chymotrypsin-treated platelets sustained 50% inhibition of fibrinogen binding when incubated with 0.4 to 0.5 mmol/L DB, and kinetic analysis showed that the high-affinity platelet-fibrinogen interactions were reduced but not absent.
platelet-fibrinogen Binding (interactions) of in platelets
9) Confidence 0.33 Published 1986 Journal Blood Section Abstract Doc Link 3015284 Disease Relevance 0 Pain Relevance 0.14
Interestingly, gpIIb/IIIa Mabs cross-reacts with the leukocyte integrin Mac-1 receptor on activated monocytes and macrophages and blocks adhesion to fibrinogen and ICAM-1 [25], which has also been implicated in the leukocyte recruitment associated with I/R [26].
gpIIb Binding (cross) of in monocytes associated with adhesions
10) Confidence 0.12 Published 2002 Journal BMC Cardiovasc Disord Section Body Doc Link PMC117121 Disease Relevance 0.87 Pain Relevance 0
RESULTS: Two types of glycoprotein IIb/IIIa complex antagonists, peptide-mimetic FK633 and abciximab and prostaglandin E(1), significantly prevented platelet loss and the increase in binding of PAC-1, an antibody specific for fibrinogen receptor on activated platelets, during extracorporeal circulation of heparinized blood.
fibrinogen receptor Binding (binding) of in platelets
11) Confidence 0.05 Published 2003 Journal J. Thorac. Cardiovasc. Surg. Section Body Doc Link 12928640 Disease Relevance 0 Pain Relevance 0
Antiaggregatory effect of ajoene may also be causally related to its direct interaction with the putative fibrinogen receptor (GPIIb/IIa) [83].
fibrinogen receptor Binding (interaction) of
12) Confidence 0.01 Published 2002 Journal Nutr J Section Body Doc Link PMC139960 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox